Nvidia, Evgo and Affirm fall premarket; Pfizer and SolarEdge rise

US stock futures fell ahead of the Federal Reserve meeting, with notable movers including Nvidia, Pfizer, and Evgo impacting market dynamics.

Pfizer projects 2025 earnings to align with expectations

Pfizer anticipates 2025 profits will align with Wall Street expectations amid a company strategy to cut costs following declining sales and investor criticisms.

Pfizer does not expect major vaccine policy changes under Trump in 2025

Insurer stocks fall after Trump says 'we're going to knock out the middleman'

Trump's criticism of pharmacy benefit managers caused shares of major health insurers to drop, igniting debate about drug pricing and proposals to eliminate middlemen in the industry.

Unsupported price hikes added $815 million to US drug spending in 2023

A report reveals five drugs accounted for $815 million in U.S. spending increases in 2023 without clinical evidence, highlighting ongoing pricing issues in the pharmaceutical industry.

Health execs reckon with patient outrage after UnitedHealthcare killing

Health care executives reassess patient experiences and security after the murder of UnitedHealth CEO Brian Thompson, deepening dialogue on healthcare corruption and systemic issues.

Lilly CEO says tax and regulation reform, drug affordability are focuses under Trump

Eli Lilly's CEO emphasized drug affordability and regulatory reforms as key focuses for a second Trump term, discussing potential collaborations in healthcare and cost reduction strategies.

BofA reinstates pharma coverage

Bank of America reviews 11 U.S. pharma stocks, highlighting growth potential and challenges amid patent cliffs and pricing pressures while recommending buy, neutral, and underperform ratings.

Trump, RFK Jr. met with Pfizer, Lilly executives, Axios reports

Trump met with drugmakers' CEOs and health industry figures to discuss collaboration on cancer cures at Mar-a-Lago, alongside controversial pick Robert F. Kennedy Jr.

Novavax to sell Czech manufacturing unit to Novo Nordisk for $200 million

Novavax sells its Czech manufacturing facility to Novo Nordisk for $200 million to boost its vaccine pipeline and reduce costs, amid struggles with COVID-19 vaccine competition.